Product Description
REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). REL-1017 works with a MOA markedly different from standard serotoninergic antidepressants. (Sourced from: https://www.relmada.com/science)
Mechanisms of Action: NMDA Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Depressive Disorder|Depressive Disorder, Major *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Relmada
Company Location: NEW YORK NY 10022
Company CEO: Sergio Traversa
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RELIANCE-II | P3 |
Recruiting |
Depressive Disorder, Major |
2024-12-01 |
|
RELIGHT | P3 |
Recruiting |
Depressive Disorder, Major |
2024-12-01 |
|
RELIANCE-OLS | P3 |
Completed |
Depressive Disorder, Major |
2023-07-27 |
|
Reliance I | P3 |
Completed |
Depressive Disorder, Major |
2022-11-01 |